Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly australians considering diabetes as comorbidity

Medicine (United States)

Volumn 94, Issue 9, 2015, Pages e590-

  Chowdhury, Enayet K ^a   Ademi, Zanfina ^a,b   Moss, John R ^c   Wing, Lindon M H ^d   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; INSULIN; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSTRALIAN; CARDIOVASCULAR DISEASE; CHRONOTHERAPY; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DIURETIC THERAPY; FEMALE; GERIATRIC PATIENT; HEALTH CARE COST; HUMAN; HYPERTENSION; INSULIN TREATMENT; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; AGE; AUSTRALIA; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITALIZATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUSTRALIA; CARDIOVASCULAR DISEASES; COMORBIDITY; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; QUALITY-ADJUSTED LIFE YEARS; SEX FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84926346355     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000590     Document Type: Article

References (45)

1. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872
2. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum-current outcomes and control in the community. JAMA. 2005;294:466-472
3. Whelton PK. Epidemiology of hypertension. Lancet. 1994;344:101-106
4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223
5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension. 2001;37:1053-1059
6. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999;33:1130-1134
7. Australian Health Survey: Health Service Usage and Health Related Actions, 2011-12 (4364.0.55.002). Australian Bureau of Statistics; 2013. http://www.abs.gov.au/AUSSTATS/abs@nsf/2f762f95845417aeca25706c00834efa/322DB1B539ACCC6CCA257B39000F316C opendocument. Accessed November 21, 2013
8. Australian Institute of Health and Welfare. Diabetes Prevalence in Australia: Detailed Estimates for 2007-08. Diabetes series no. 17. Cat. no. CVD 56. Canberra: AIHW 2011
9. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011;123:933-944
10. Department of Health and Ageing-Medicines Australia. Expenditure and Prescriptions Twelve Months to 30 June 2012. Canberra: PBS Information Management Section Pharmaceutical Policy Branch; 2013. http://www.pbs.gov.au/info/statistics/expenditure-andprescriptions-30-06-2012
11. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006. Article: CD005182
12. Turnbull F, Neal B, Algert C, et al. Effects of different bloodpressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535
13. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357
14. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15
15. Tran K, Ho C, Noorani H, et al. Thiazide Diuretics as First-Line Treatment for Hypertension: Meta-analysis and Economic Evaluation Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007
16. National Collaborating Centre for Chronic Conditions (UK). Hypertension: Management in Adults in Primary Care: Pharmacological Update. London, UK: Royal College of Physicians; 2006. (NICE Clinical Guidelines, No. 34.) http://www.ncbi.nlm.nih.gov/books/NBK45886/
17. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3-10
18. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006;29:1065-1070
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997
20. Chowdhury EK, Owen A, Ademi Z, et al. Short-and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure Study. Am J Hypertens. 2014;27:199-206
21. Heidenreich PA, Davis BR, Cutler JA, et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: An analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med. 2008;23:509-516
22. Nordmann AJ, Krahn M, Logan AG, et al. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy. Pharmacoeconomics. 2003;21:573-585
23. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592
24. Pharmaceutical Benefits Scheme. http://www.pbs.gov.au. Accessed Mar 02, 2013
25. Public Sector Estimated Cost Weights Round 13 AR-DRG v5.2 http://www.health.gov.au/internet/main/publishing.nsf/Content/Round-13-cost-reports. Accessed March 3, 2013
26. Medicare Benefits Schedule (MBS). http://www.mbsonline.gov.au/. Accessed February 10, 2013
27. National Collaborating Centre for Chronic Conditions (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. Available from: http://www.ncbi.nlm.nih.gov/books/NBK83274/. 2011. Accessed June 10, 2013
28. Ara R, Wailoo AJ. NICE DSU Technical Support Document 12: The Use of Health State Utility Values in Decision Models. Decision Support Unit, School of Health and Related Research, University of Sheffield; 2011. http://www.nicedsu.org.uk
29. Howard K, Salkeld G, White S, et al. Cost-Effectiveness of Early Detection and Intervention to Prevent Progression of Chronic Kidney Disease in Australia. Kidney Health Australia; 2006. http://www. kidney.org.au
30. Ademi Z, Liew D, Hollingsworth B, et al. The economic implications of treating atherothrombotic disease in Australia, from the government perspective. Clin Ther. 2010;32:119-132
31. Dunstan D, Zimmet P, Welborn T, et al. Diabesity and Associated Disorders in Australia, 2000: The Accelerating Epidemic. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Melbourne: International Diabetes Institute; 2001
32. Australian Institute of Health and Welfare (AIHW). Health Expenditure Australia 2011-12. Health and welfare expenditure series no
33. Cat. no. HWE 59. Canberra: AIHW; 2013. https://www.aihw. gov.au/WorkArea/DownloadAsset.aspxid=60129544656. Accessed January 11, 2014
34. Smith SM, Campbell JD. Cost-effectiveness of renin-guided treatment of hypertension. Am J Hypertens. 2013;26:1303-1310
35. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: The ongoing debate. Value Health. 2004;7:397-401
36. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994-2004. Med Decis Mak. 2008;28:713-722
37. George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making-evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001;19:1103-1109
38. Wright JM, Musini VM. First-line drugs for hypertension (Review). Cochrane Database Syst Rev. 2009. Article: CD001841
39. Lamy A, Yusuf S, Pogue J, et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003;107:960-965
40. Briggs A, Mihaylova B, Sculpher M, et al. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart. 2007;93:1081-1086
41. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, Switzerland: World Health Organization; 2009
42. Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31:982-988
43. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29-35
44. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026-2033
45. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med. 2003;139:244-252